News &amp; Events

News & Events

News

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

6 Oct, 2026

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

13 Aug, 2026

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

10 Aug, 2026

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

13 Jul, 2026

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Lymph Node Research UK launches with national network of ten specialist research centres

16 Jun, 2026

Oxford, 16 June 2026: A new £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease has launched, bringing together ten specialist centres across the country.

Ebola: vaccines alone won’t stop an outbreak – here’s what else is needed

8 Jun, 2026

(Published on The Conversation) Tensions have recently emerged around the Ebola response in eastern Democratic Republic of the Congo (DRC). These tensions have manifested in a series of incidents, including the burning of an Ebola treatment facility in Mongbwalu, confrontations involving families seeking to reclaim the bodies of relatives who had died from the disease, and reports of police firing warning shots. These events serve as a reminder that outbreaks are rarely controlled by vaccines alone.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

1 Jun, 2026

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

22 May, 2026

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Dr Young Chan Kim receives international vaccine research award

19 May, 2026

Dr Young Chan Kim has been awarded the 2026 Early Career Researcher Award at the 20th Vaccine Congress, one of the leading international conferences in vaccinology organised by Vaccine, Elsevier’s premier journal in the field.

The meningitis vaccine now sits at the centre of two health crises

31 Mar, 2026

(Published on The Conversation) The UK has recently seen a resurgence of meningococcal B (MenB) disease, with a cluster of cases in Kent described as “unprecedented” by the health secretary, Wes Streeting. As attention turns from the current MenB outbreak to how to prevent future outbreaks, another challenge is also growing: gonorrhoea is becoming harder to treat as antibiotic resistance rises. These two challenges might seem unrelated, but they are now linked by a single vaccine.

The UK’s childhood vaccination schedule just changed. Here’s why that’s actually reassuring

12 Jan, 2026

(Published on The Conversation) The UK has updated its childhood immunisation schedule. For parents who had already mapped out their child’s vaccination appointments in their heads, the announcement might have come as an unwelcome surprise.

Ambitious research aims to develop multivalent vaccines to protect against multiple deadly filoviruses

8 Jan, 2026

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

More news & archive ❯

Upcoming events

Online Immunisation Update Training: Tues 10 Nov 2026

Tuesday, 10 November 2026, 9am to 12.45pm @ Online

A half-day online immunisation update training course, delivered via Microsoft Teams. This training is primarily targeted at healthcare professionals and healthcare support workers who already administer, promote and/or advise about vaccines. 3.5 CPD hours of participatory learning.

More events & archive ❯

Cookies on this website